Greater access to key treatment option for patients with rare flesh eating ulcer

There’s new hope for Australians living with a severe flesh eating ulcer, with expanded subsidised access to a key medicine on the Pharmaceutical Benefits Scheme (PBS). From 1 December, access to Rimycin 150® and 300® (rifampicin) will be expanded on the PBS for the treatment of Buruli ulcer (Mycobacterium ulcerans infection). It is expected 425…